During the period of time from 2023 to 2029, the global market for cell and gene therapy Contract Development and Manufacturing Organization (CDMO) services is projected to grow at a compound annual growth rate (CAGR) of 17.5%. In 2022, the market was valued at USD 5,193.7 million. Several factors contribute to this growth, including the expanding pipeline of cell and gene therapy candidates and patients, the growing investment in cell and gene therapy,increasing tendencies in outsourcing, improving manufacturing technology, growing acceptance of new therapies, and supportive regulatory frameworks. The fact that chronic illnesses such as heart problems, genetic abnormalities, cancer, and autoimmune diseases are prevalent all over the globe is another factor that contributes to the growing momentum enjoyed by this industry.
The CAGT offers the ability to treat both inherited and acquired disorders by focusing on the underlying causes of these conditions. It provides ideas and methods that may be used to reproductive potential, remodeling, and the control of genes. The United States of America is experiencing a rising acceptance of gene therapy in the fields of diagnostics, treatments, and research connected to cancer and clinical illnesses. In the future, the expansion of the Cell and Gene Therapy CDMO Services Market is anticipated to be driven by a number of factors, including an increasing elderly population and an increase in infectious illnesses all over the globe. Additionally, the development of the market is further contributed to by the expenditures made by industry participants in the introduction of new products and clinical studies.
Cell therapy is expected to become the dominant field, and the United States of America is a target for cell and gene therapy contract manufacturing organizations (CDMOS), with large acquisitions taking place in the region. The need for CDMOs from newer firms in the pharmaceutical and biotechnology industries, in conjunction with the benefits that these companies provide, generates market growth potential that are very profitable.
The Market for CDMO Services:
There are many types of therapies that are used to categorize the worldwide market for cell and gene therapy CDMO services. Gene therapy, which covers both viral and non-viral vectors, as well as cell therapy (autologous, allogeneic, and viral vector) are included in this program. Based on significant pre-clinical studies that concentrate on cell biology, mechanism of action, phenotypic effectiveness, and immunology, it is anticipated that the cell therapy sector will earn a bigger revenue share, particularly in the field of cardiovascular disease research. In particular, allogenic treatment provides cells that are highly functioning and easily accessible for research purposes. It is projected that these factors will push the expansion of the Cell and Gene treatment CDMO Services market, which is further divided based on the kind of treatment, the application, the therapeutic area, the end user, and the geographic location.
The market is further segmented into additional categories based on application, such as clinical manufacturing and commercial manufacturing, in addition to classifications depending on the kind of treatment being prescribed. A number of subspecialties, including Oncology, Orthopedics, Infectious Disease, Cardiovascular Disease, and Others, are included in the therapeutic area section. As an additional point of interest, the end-user category includes companies in the pharmaceutical and biotechnology industries, academic and research institutions, and other organizations.
Market participants in the worldwide Cell and Gene Therapy CDMO Services business are using methods such as strategic new product releases, mergers, acquisitions, and partnerships in order to strengthen their position in the market. According to the findings of the market study, prominent players are placing a greater emphasis on the introduction of novel goods, the execution of product launches, and the formation of long-term partnerships in order to increase their market share and build a strong presence in a variety of geographical locations.
There are a number of notable companies that are currently operating in the market for cell and gene therapy CDMO services. These companies include FUJIFILM Holdings Corporation, Charles River Laboratories, Wuxi AppTec, Merck KGaA, Oxford Biomedica Plc, Cell & Gene Therapy Catapult, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche LTD., Lonza, Catalent, and Takara Bio-Inc.
